Q3 2025 EPS Estimates for Bruker Co. Decreased by Analyst (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for shares of Bruker in a research note issued on Wednesday, September 18th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.94 per share for the quarter, down from their prior forecast of $0.96. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The firm had revenue of $800.70 million during the quarter, compared to analysts’ expectations of $799.44 million. During the same quarter in the previous year, the business earned $0.50 earnings per share. The firm’s revenue was up 17.4% compared to the same quarter last year.

Several other analysts also recently weighed in on BRKR. The Goldman Sachs Group reduced their target price on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Citigroup decreased their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. Wells Fargo & Company began coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price on the stock. Jefferies Financial Group began coverage on shares of Bruker in a research note on Monday, June 3rd. They set a “buy” rating and a $85.00 price target for the company. Finally, TD Cowen dropped their price objective on shares of Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.40.

Bruker Price Performance

Shares of BRKR opened at $68.32 on Monday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker has a 1-year low of $53.79 and a 1-year high of $94.86. The stock has a market cap of $9.93 billion, a PE ratio of 24.84, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. The firm has a fifty day moving average price of $64.68 and a 200 day moving average price of $72.30.

Institutional Investors Weigh In On Bruker

Institutional investors have recently modified their holdings of the company. Centaurus Financial Inc. purchased a new stake in Bruker during the second quarter worth $291,000. Sanctuary Advisors LLC purchased a new stake in shares of Bruker in the 2nd quarter worth about $296,000. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker in the 2nd quarter worth about $52,000. Maven Securities LTD grew its stake in Bruker by 400.0% in the 2nd quarter. Maven Securities LTD now owns 20,000 shares of the medical research company’s stock valued at $1,276,000 after acquiring an additional 16,000 shares during the last quarter. Finally, Aristides Capital LLC acquired a new position in Bruker during the second quarter worth about $222,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio is currently 7.27%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.